Publications by authors named "Laida Elberdin"
Article Synopsis
- Measuring trough concentrations of biological drugs and anti-drug antibodies is important for optimizing treatments, with ELISA being the traditional method used.
- A study compared drug levels and antibody concentrations using a new chemiluminescence technique (i-TRACK) to the established ELISA method (TRITURUS) for drugs like infliximab, adalimumab, vedolizumab, and ustekinumab.
- While both methods showed excellent correlation for measuring drug concentrations, the chemiluminescent technique generally reported lower values, and further research is needed for ustekinumab and vedolizumab due to modest results.
Introduction: There is growing evidence that therapeutic drug monitoring of biologic therapy is beneficial in psoriatic patients. With respect to ustekinumab, the available evidence has not shown any relationship yet. The objective of this study is to identify correlations among ustekinumab trough concentrations, anti-ustekinumab antibodies and clinical response in moderate-to-severe plaque psoriasis patients, in a real-world setting.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to analyze the effectiveness and long-term use of biologic therapies in patients with moderate to severe plaque-type psoriasis who started treatment at least 10 years prior.
- It involved 56 patients tracked over time, with most continuing therapy; the average treatment duration was about 140 months, focusing on various biologics like etanercept and ustekinumab.
- Findings indicated that biologic therapies maintained efficacy and safety over the long term, with ustekinumab showing the highest retention rate among patients.
Background In the case of psoriatic patients, only a limited number of studies have related serum biological therapies and antidrug antibodies levels to clinical response. With respect to etanercept, the available evidence has not shown any relationship yet. Objective The aim of this study was to determine if there is any correlation among etanercept serum levels, the presence of anti-etanercept antibodies and clinical response to this treatment in psoriatic patients.
View Article and Find Full Text PDFIntroduction: Knowledge on the efficacy and safety of adalimumab in psoriasis patients switching from etanercept is scarce, especially on the influence that causes of etanercept discontinuation may have on adalimumab response.
Objectives: To evaluate the response, adverse effects and factors that may influence the efficacy and safety of adalimumab in psoriasis patients who failed on etanercept therapy in a real-world setting.
Methods: Data from all moderate to severe plaque psoriasis patients who switched from etanercept to adalimumab were extracted from a registry of biological therapies of our department.